UK markets closed

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.5777+0.0076 (+1.33%)
As of 02:04PM EDT. Market open.
Sign in to post a message.
  • F
    FACHA BRUTE
    Whoa. Who puked up ~ 85,000 shares just now, and more importantly, who bought them? (Nice stacking)
  • F
    FACHA BRUTE
    I dunno about the rest of you, but I love to weather the storm in a float locker stock.
  • B
    Bob
    We may not have any news about AgeX's pipeline these days. But from a technical perspective, AgeX intrigues here:

    Golden Cross: On Tuesday, we're due for AGE's second ever Golden Cross (50 day moving average crossing up through the 200 day moving average). And it should last for a while as the 200DMA works off higher prices from mid-2022. Also note, AgeX's other golden cross was within a week of the mighty one-day 4.5x spike on 10/8/20.

    Fractals: If you look at AgeX's chart since inception (30 months of chart), The pattern formed over first 15 months looks like a slightly shorter, but otherwise rather close cousin of the pattern formed (and looking completed) over the last 15 months. And sure enough, the 15 month original pattern ended on that same 10/6/20 spike day.

    Float Locker: With only 791k shares traded here in May, AGE looks likely to have its first ever monthly trading volume under 1mm shares. That's a monthly turnover of around 2% of the float. Even if you take Juvenescence's massive stake out of the picture, that's still only around 4% of the remaining float traded all month, not to mention some of those shares were probably the same ones being passed around. So more likely only 2-3% of non-Juvenescence shares were traded all month, with ~98% of all other AGE shareholders holding tight here. This has been highlighted several times this month when buyers have stepped in and the spread has quickly jumped up 10+ cents, with the difference in bid/ask stretching out to 10-25% at times.

    Personally, I can't recall seeing a technical setup quite like one. It's even more surprising how tidy the patterns are despite massively illiquid AGE trading as little as $2400 in daily volume earlier this month. I generally tend to be early in my predictions, but I can't help but think the AGE chart looks ripe here.
  • B
    Bob
    Something to consider: at today's rock bottom share prices, Juvenescence essentially has claim to nearly all of AgeX's meager ~$25mm market cap between its convertible debt and massive share ownership. Every time Juvenescence deploys another year's worth of $7mm in precious capital to fund AgeX operating expenses, it would stand to reason they believe AgeX will not only be worth another $7mm some day (18 cents per share), but also provide a meaningful return on the $23mm in debt they will have deployed in the project by around year end, not to mention express value to potential IPO investors.
  • B
    Bob
    New Senior Accountant. New Board Chair. New chapter for AgeX?
  • F
    FACHA BRUTE
    What we need is a good old fashioned sellers strike. There was a 20%+ spread between bid and ask this morning. Far be it from me to say anyone should't take a profit if they want/need to, but this stock is just begging for some buyers pressure, see also, @Bob's post from yesterday.
  • P
    Peter
    The friendly competition celebrates early. 🤣

    https://mobile.twitter.com/GotfrydKarol/status/1528336989250105344
  • B
    Bob
    Today we saw the all-time record low daily volume at 3165 shares. Of course, there is little difference between that and a few thousand more as we have often seen over the past month. My theory? Many have stocked up here near the all-time lows, and the cupboard is bare.
  • B
    Bob
    The volume beast has slinked away to the shadows again. We just posted the all-time low weekly volume at 76k shares this week, easily shattering the previous low of 110k from 2 weeks ago. Interestingly the XBI (S&P Biotech ETF) had its 3rd highest ever volume week in rather stark contrast to AGE, not to mention XBI is just 1 bad day from its Covid panic low. But wait, did I forget to mention the biggest news out of AgeX in 2022: they are hiring an accountant. This week on their website they posted a job in their brand new Careers tab for a Senior Accountant: https://www.agexinc.com/careers/ My favorite listed duty? "Daily posting of vendor invoices (to hire AP accountant when volume increases.)" That sure would be a lot bean counters for a staff of 6. Almost sounds like a big shipment of beans coming their way soon.
    AgeX Therapeutics | Careers
    www.agexinc.com
  • B
    Bob
    Record low weekly volume on AGE last week at 110k shares. That comes the week after the third lowest week ever at 140k shares. Feels like a trading halt courtesy of the market itself. Can't wait until the announcement after which market agrees to resume trading.
  • F
    FACHA BRUTE
    Current AGE volume:
  • F
    FACHA BRUTE
    Market responds to AGE Q1/22 Earnings by...let me check my notes...ahhhh yes, with trading volumes that are less than AGE's revenue of $5000 by 2:08 EST.

    By all accounts AGE should have been cut in half today, yet, silence. All of this makes me say... $27M Market Cap my rosy rear end. We're clearly going higher, as we're clearly not going down.
  • B
    Bob
    Let's revisit something I've been thinking since AgeX got spun out 3.5(!) years ago. AgeX *still* does not have a lot of shares available for retail holders, appx 14mm by my calculations in the table below (about $12.5mm currently). That's only enough room for 100 investors at $125k each. If AgeX (or Partial Reprogramming) ever gets some serious credibility and/or press, it wouldn't take many diamond hands holders to lock the float up for the only existing retail pure play on it. And arguably, this story (let's all get healthier/younger) could have far more general appeal than GME (let's fry the shorts) or BTC (let's take over global trade). Should this come to pass, what would we call ourselves? Eternals? Lifers? Immortalists? Westies? It's a tricky business. Much easier to come up with the obvious corporate softball team mascot: the AgeX Axolotls.

    AgeX Ownership Shares Percent
    Current Float 37,940,000 100%
    Juvenescence 16,837,817 44%
    Broadwood Capital 2,003,446 8%
    Institutional Holders 2,769,104 7%
    Alfred Kingsley 700,000 2%
    Total Held Tightly 23,310,367 61%
    Free to Trade 14,629,633 39%
  • B
    Bob
    Gonna try to list the items from the shareholders call that sounded like potential 2022 events:

    1. Partnership to develop BAT-1 if proof of concept study is successful (data shared in 2022)
    2. Pursue strategic options for Univercyte over the course of the next year
    3. Pursue strategic options for VASC-1 over the course of the next year
    4. Pursue strategic options for PureStem over the course of the next year
    5. Developing a 50/50 split partnership with UC Irvine (neural cells, exosomes) "early in the new year"
    6. Exploring other ways in which we might acquire and co-develop or license technologies that will lead to the development of innovative cell therapies
    7. "Go faster with equity financing for Reverse, which is what we plan to do." (my note: this might apply to Renelon and/or EPRO)
    8. Some of the "Ten Additional iTR, iTM Patent Families filed" between 2018-2021 rolling in.
    9. CardioStem - We plan to either partner or develop with a subsidiary, independently funded from the company, with the potential to be a near-term product.
    10. Non-EPRO-related diagnostic uses of our technologies, which we plan to either partner or develop with a subsidiary, independently funded from the company, with the potential to be a near-term product.
  • P
    Peter
    New Twitter account on AgeX and iTR

    https://mobile.twitter.com/ResetYourClock
  • D
    DT
    I’m new to this whole discussion (about a year) and concept of slowing of ageing and cell regeneration. It’s fascinating that this technology / medicine is where it’s at today. I’m optimistic there is much more to come. That said, JUV has interests in multiple companies and are entrepreneurs in this industry. I would like to see JUV go public, to better understand these relationships, short- and long-term strategies. One thought I had about this is why doesn’t JUV acquire AGEX and rebrand as AGEX instead of an IPO? It doesn’t appear they need the typical revenue from an IPO.
  • F
    Felix
    There’s a new preprint from the AgeX crew posted on April 14th titled “No Time to Age: Uncoupling Aging from Chronological Time”. The paper is a comprehensive overview of the diverse observations and discoveries relating to aging over the past few decades and how they fit into and support AgeX’s unifying somatic restriction hypothesis.

    I liked this framing: “Given the astonishing degree of phenotypic plasticity observed in the forward and reverse programming of development and aging in nature and in the laboratory, we may perhaps view young and old organisms as 2 epigenetic states of the same genome with the young state contained (as information) within the old, and the old state contained in the young as a potentiality that becomes actualized by the ticking of the cellular clocks with the passage of time. If aging is indeed a continuation of development as suggested by the behavior of cellular aging clocks, then it is not surprising that reprogramming can reverse the forward programming of both development and aging.”

    They also suggested that mRNA delivery could benefit from the progress of recent COVID vaccines, which might be a hint about AgeX’s gene therapy formulation. Between this and the protocadherin preprint, it looks like they are preparing to lift the veil on iTR and launch Reverse Bio sometime in the near future.
  • B
    Bob
    A little speculation as AGE climbs after the shelf registration. Perhaps AGE is positioning themselves to take advantage of a share price boost following some good news. Probably not anything with an upfront attached to it, otherwise who needs the money? But perhaps the lid will be lifted on HLA-G or iTR research, as Greg Bailey suggested in the end of year letter. And if readers here, along with the Yahoo! bots, will allow me to speculate on my speculation, I might even be so bold as to suggest AGE wouldn't issue a shelf statement unless it intended to use it within say a quarter. Otherwise, it would perhaps be wiser to save the money, wait until later and tailor the shelf to more up-to-date conditions. Or in short, maybe AGE has some good news for us soon. The market seems to be acting that way, at least for the past 3 days.